Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol vs Atorvastatin for CIN Prevention
NCT03867994Phase 2Completed
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of carvedilol in contrast-induced nephropathy (CIN). Primary endpoint: Development of Contrast-Induced Nephropathy. Started Feb 2016; status: completed.
02
Drugs
carvedilol
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT03867994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867994.